State Street Corp lessened its holdings in Horizon Therapeutics PLC (NASDAQ:HZNP) by 0.5% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,584,939 shares of the biopharmaceutical company’s stock after selling 11,830 shares during the quarter. State Street Corp owned 1.38% of Horizon Therapeutics worth $70,388,000 as of its most recent SEC filing.
Several other hedge funds have also added to or reduced their stakes in the stock. Quadrant Capital Group LLC acquired a new stake in Horizon Therapeutics during the third quarter worth approximately $66,000. Steward Partners Investment Advisory LLC bought a new stake in shares of Horizon Therapeutics during the 2nd quarter valued at $76,000. Tower Research Capital LLC TRC lifted its position in shares of Horizon Therapeutics by 384.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 3,389 shares of the biopharmaceutical company’s stock valued at $82,000 after acquiring an additional 2,689 shares during the period. Advisory Services Network LLC grew its holdings in shares of Horizon Therapeutics by 1,100.3% during the 2nd quarter. Advisory Services Network LLC now owns 3,469 shares of the biopharmaceutical company’s stock worth $83,000 after purchasing an additional 3,180 shares in the last quarter. Finally, Bank of Montreal Can grew its holdings in shares of Horizon Therapeutics by 45.7% during the 2nd quarter. Bank of Montreal Can now owns 3,831 shares of the biopharmaceutical company’s stock worth $92,000 after purchasing an additional 1,201 shares in the last quarter. Institutional investors and hedge funds own 88.24% of the company’s stock.
A number of research firms recently commented on HZNP. Bank of America began coverage on Horizon Therapeutics in a research note on Thursday, September 26th. They issued a “buy” rating and a $34.00 price target for the company. ValuEngine cut shares of Horizon Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, September 5th. Cantor Fitzgerald increased their price objective on shares of Horizon Therapeutics from $32.00 to $36.00 and gave the stock an “overweight” rating in a research note on Friday, November 8th. Guggenheim began coverage on shares of Horizon Therapeutics in a report on Thursday, September 12th. They issued a “buy” rating and a $36.00 target price on the stock. Finally, BidaskClub upgraded shares of Horizon Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, November 28th. Three analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $33.77.
Horizon Therapeutics (NASDAQ:HZNP) last released its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $0.64 earnings per share for the quarter, beating the consensus estimate of $0.50 by $0.14. Horizon Therapeutics had a return on equity of 27.71% and a net margin of 5.25%. The business had revenue of $335.50 million for the quarter, compared to analyst estimates of $330.60 million. During the same period last year, the firm posted $0.65 earnings per share. Horizon Therapeutics’s revenue was up 3.1% compared to the same quarter last year. On average, research analysts forecast that Horizon Therapeutics PLC will post 1.55 earnings per share for the current year.
In other Horizon Therapeutics news, EVP Irina Konstantinovsky sold 17,838 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $26.70, for a total value of $476,274.60. Following the sale, the executive vice president now owns 44,819 shares in the company, valued at $1,196,667.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director James Samuel Shannon sold 15,500 shares of the business’s stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $26.59, for a total transaction of $412,145.00. Following the sale, the director now directly owns 15,500 shares in the company, valued at approximately $412,145. The disclosure for this sale can be found here. In the last three months, insiders have sold 395,956 shares of company stock valued at $11,118,487. Insiders own 4.10% of the company’s stock.
Horizon Therapeutics Company Profile
Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.
Featured Article: Determine Your Level of Risk Tolerance
Receive News & Ratings for Horizon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.